These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 30155893)

  • 21. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy.
    Hajiran A; Azizi M; Aydin AM; Zemp L; Peyton CC; Dhillon J; Nealon S; Reich RR; Cao B; Li R; Manley BJ; Sexton WJ; Gilbert SM
    J Urol; 2021 Jan; 205(1):100-108. PubMed ID: 32783489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathological downstaging following radical cystectomy for muscle-invasive bladder cancer: Survival outcomes in the setting of neoadjuvant chemotherapy versus transurethral resection only.
    Cajipe M; Wang H; Elshabrawy A; Kaushik D; Liss M; Svatek R; Wu S; Chowdhury WH; Ramamurthy C; Mansour AM
    Urol Oncol; 2020 Apr; 38(4):231-239. PubMed ID: 31956078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.
    Necchi A; Anichini A; Raggi D; Briganti A; Massa S; Lucianò R; Colecchia M; Giannatempo P; Mortarini R; Bianchi M; Farè E; Monopoli F; Colombo R; Gallina A; Salonia A; Messina A; Ali SM; Madison R; Ross JS; Chung JH; Salvioni R; Mariani L; Montorsi F
    J Clin Oncol; 2018 Dec; 36(34):3353-3360. PubMed ID: 30343614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemotherapy in the treatment of muscle invasive bladder cancer with mixed histology.
    Lin J; Whalen M; Holder D; Hruby G; Decastro GJ; McKiernan J
    Can J Urol; 2013 Apr; 20(2):6690-5. PubMed ID: 23587508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistent muscle-invasive bladder cancer after neoadjuvant chemotherapy: an analysis of Surveillance, Epidemiology and End Results-Medicare data.
    Lane G; Risk M; Fan Y; Krishna S; Konety B
    BJU Int; 2019 May; 123(5):818-825. PubMed ID: 30126053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle-invasive Urothelial Carcinoma of the Bladder.
    Hensley PJ; Goodwin J; Davenport DL; Strup SE; James A
    Clin Genitourin Cancer; 2018 Aug; 16(4):e851-e858. PubMed ID: 29548614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longer time to radical cystectomy in patients treated with neoadjuvant chemotherapy is associated with worse oncological outcomes.
    Nuijens ST; van Osch FHM; van Hoogstraten LMC; Witjes JA; Aben KKH; Hermans TJN
    Urol Oncol; 2024 Apr; 42(4):117.e11-117.e16. PubMed ID: 38238116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future.
    Hermans TJN; Voskuilen CS; van der Heijden MS; Schmitz-Dräger BJ; Kassouf W; Seiler R; Kamat AM; Grivas P; Kiltie AE; Black PC; van Rhijn BWG
    Urol Oncol; 2018 Sep; 36(9):413-422. PubMed ID: 29128420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Outcomes After Neoadjuvant Chemotherapy and Radical Cystectomy in the Presence of Urothelial Carcinoma of the Bladder With Squamous or Glandular Differentiation.
    Zargar-Shoshtari K; Sverrisson EF; Sharma P; Gupta S; Poch MA; Pow-Sang JM; Spiess PE; Sexton WJ
    Clin Genitourin Cancer; 2016 Feb; 14(1):82-8. PubMed ID: 26411593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy.
    Seisen T; Jamzadeh A; Leow JJ; Rouprêt M; Cole AP; Lipsitz SR; Kibel AS; Nguyen PL; Sun M; Menon M; Bellmunt J; Choueiri TK; Trinh QD
    JAMA Oncol; 2018 Feb; 4(2):225-229. PubMed ID: 28837718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncologic outcomes of neoadjuvant chemotherapy in patients with micropapillary variant urothelial carcinoma of the bladder.
    Rahman SN; Lokeshwar SD; Syed JS; Javier-Desloges JF; Press BH; Choksi AU; Rajwa P; Pradere B; Ploussard G; Kim JW; Monaghan TF; Renzulli JR; Shariat SF; Leapman MS
    Urol Oncol; 2023 Feb; 41(2):107.e1-107.e8. PubMed ID: 36481253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of neoadjuvant chemotherapy with four cycles of dose-dense MVAC followed by radical cystectomy in Korean patients with muscle-invasive or locally advanced urothelial carcinoma of bladder.
    Park K; Lee HJ; Kim TU; Ryu H; Ki YK; Hong YJ; Nam JK
    Asia Pac J Clin Oncol; 2023 Dec; 19(6):739-746. PubMed ID: 37461246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and therapeutic factors associated with adverse pathological outcomes in clinically node-negative patients treated with neoadjuvant cisplatin-based chemotherapy and radical cystectomy.
    Zargar-Shoshtari K; Zargar H; Dinney CP; Ercole CE; Sharma P; Kovac E; Grivas PD; Stephenson AJ; Shah JB; Black PC; Spiess PE
    World J Urol; 2016 May; 34(5):695-701. PubMed ID: 26286880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Occult Nodal Metastases in Patients Down-Staged to Nonmuscle Invasive Disease Following Neoadjuvant Chemotherapy.
    Nassiri N; Ghodoussipour S; Maas M; Nazemi A; Asanad K; Pearce S; Bhanvadia SS; Djaladat H; Schuckman A; Daneshmand S
    Urology; 2020 Aug; 142():155-160. PubMed ID: 32268173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant Chemotherapy for Different Stages of Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Liu S; Yao Y; Guan F; Sun L; Zhang G
    Dis Markers; 2022; 2022():8493519. PubMed ID: 35280442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical role of additional adjuvant chemotherapy in patients with locally advanced urothelial carcinoma following neoadjuvant chemotherapy and cystectomy.
    Zargar-Shoshtari K; Kongnyuy M; Sharma P; Fishman MN; Gilbert SM; Poch MA; Pow-Sang JM; Spiess PE; Zhang J; Sexton WJ
    World J Urol; 2016 Nov; 34(11):1567-1573. PubMed ID: 27072536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy.
    Bree KK; Hensley PJ; Westerman ME; Kokorovic A; Nogueras-Gonzalez GM; Dinney CP; Kamat AM; Navai N
    J Urol; 2021 Sep; 206(3):577-585. PubMed ID: 33872050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder.
    Softness K; Kaul S; Fleishman A; Efstathiou J; Bellmunt J; Kim SP; Korets R; Chang P; Wagner A; Olumi AF; Gershman B
    Urol Oncol; 2022 Jun; 40(6):272.e1-272.e9. PubMed ID: 35058142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy.
    Culp SH; Dickstein RJ; Grossman HB; Pretzsch SM; Porten S; Daneshmand S; Cai J; Groshen S; Siefker-Radtke A; Millikan RE; Czerniak B; Navai N; Wszolek MF; Kamat AM; Dinney CP
    J Urol; 2014 Jan; 191(1):40-7. PubMed ID: 23911605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.